STING-Activating nanoplatforms for image-guided sonodynamic cancer therapy.

IF 33.9 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular Cancer Pub Date : 2026-02-09 DOI:10.1186/s12943-026-02591-z

Lingpu Zhang, Delong Huang, Jia Li, Linzhen Mo, Tian Qin, Bowen Xing, Bing Xiao, Chun Xu, Haihua Xiao, Leli Zeng, Kun Shang

{"title":"STING-Activating nanoplatforms for image-guided sonodynamic cancer therapy.","authors":"Lingpu Zhang, Delong Huang, Jia Li, Linzhen Mo, Tian Qin, Bowen Xing, Bing Xiao, Chun Xu, Haihua Xiao, Leli Zeng, Kun Shang","doi":"10.1186/s12943-026-02591-z","DOIUrl":null,"url":null,"abstract":"Tumor precision treatment still faces the challenge of being unable to achieve real-time monitoring. The rapid advancements in nanomedicine within the biomedical sector have highlighted the potential of integrated nano-platforms for tumor diagnosis and treatment. Herein, we create a multimodal diagnostic nanodrug, ⁹⁹mTc-NPAIE-MSA, which combines sonosensitizers, STING agonists, and radionuclides for immuno-sonodynamic therapy targeting breast cancer. This platform utilizes polymers with aggregation-induced luminescence properties that, when activated by US, generate cytotoxic reactive oxygen species, causing DNA and mitochondrial damage, activating the cGAS-STING pathway, and releasing the STING agonist MSA-2 to enhance the immune response. Additionally, ⁹⁹mTc incorporation facilitates SPECT/CT and near-infrared fluorescence imaging, thereby improving tumor targeting and therapeutic monitoring precision. Both in vitro and in vivo studies confirm the significant anti-tumor effects and immunomodulation achieved by this nano-platform under US, presenting a novel strategy for precise tumor diagnosis and treatment.","PeriodicalId":19000,"journal":{"name":"Molecular Cancer","volume":" ","pages":""},"PeriodicalIF":33.9000,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12983522/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12943-026-02591-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Tumor precision treatment still faces the challenge of being unable to achieve real-time monitoring. The rapid advancements in nanomedicine within the biomedical sector have highlighted the potential of integrated nano-platforms for tumor diagnosis and treatment. Herein, we create a multimodal diagnostic nanodrug, ⁹⁹^mTc-NP^AIE-MSA, which combines sonosensitizers, STING agonists, and radionuclides for immuno-sonodynamic therapy targeting breast cancer. This platform utilizes polymers with aggregation-induced luminescence properties that, when activated by US, generate cytotoxic reactive oxygen species, causing DNA and mitochondrial damage, activating the cGAS-STING pathway, and releasing the STING agonist MSA-2 to enhance the immune response. Additionally, ⁹⁹^mTc incorporation facilitates SPECT/CT and near-infrared fluorescence imaging, thereby improving tumor targeting and therapeutic monitoring precision. Both in vitro and in vivo studies confirm the significant anti-tumor effects and immunomodulation achieved by this nano-platform under US, presenting a novel strategy for precise tumor diagnosis and treatment.

查看原文本刊更多论文

用于图像引导声动力癌症治疗的sting激活纳米平台。

肿瘤精准治疗仍然面临着无法实现实时监测的挑战。生物医学领域纳米医学的快速发展凸显了综合纳米平台用于肿瘤诊断和治疗的潜力。在此，我们创建了一种多模态诊断纳米药物，⁹mtc - npai - msa，它结合了声敏剂、STING激动剂和放射性核素，用于针对乳腺癌的免疫声动力治疗。该平台利用具有聚集诱导发光特性的聚合物，当被US激活时，产生细胞毒性活性氧，引起DNA和线粒体损伤，激活cGAS-STING途径，并释放STING激动剂MSA-2以增强免疫反应。此外，mTc的掺入有助于SPECT/CT和近红外荧光成像，从而提高肿瘤靶向性和治疗监测精度。体外和体内研究均证实了该纳米平台在US下具有显著的抗肿瘤作用和免疫调节作用，为肿瘤的精确诊断和治疗提供了一种新的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Cancer 医学-生化与分子生物学

CiteScore

54.90

自引率

2.70%

发文量

224

审稿时长

2 months

期刊介绍： Molecular Cancer is a platform that encourages the exchange of ideas and discoveries in the field of cancer research, particularly focusing on the molecular aspects. Our goal is to facilitate discussions and provide insights into various areas of cancer and related biomedical science. We welcome articles from basic, translational, and clinical research that contribute to the advancement of understanding, prevention, diagnosis, and treatment of cancer. The scope of topics covered in Molecular Cancer is diverse and inclusive. These include, but are not limited to, cell and tumor biology, angiogenesis, utilizing animal models, understanding metastasis, exploring cancer antigens and the immune response, investigating cellular signaling and molecular biology, examining epidemiology, genetic and molecular profiling of cancer, identifying molecular targets, studying cancer stem cells, exploring DNA damage and repair mechanisms, analyzing cell cycle regulation, investigating apoptosis, exploring molecular virology, and evaluating vaccine and antibody-based cancer therapies. Molecular Cancer serves as an important platform for sharing exciting discoveries in cancer-related research. It offers an unparalleled opportunity to communicate information to both specialists and the general public. The online presence of Molecular Cancer enables immediate publication of accepted articles and facilitates the presentation of large datasets and supplementary information. This ensures that new research is efficiently and rapidly disseminated to the scientific community.